multiple sclerosis

failure crash no fail rocket cancelled end
Biotech

Sanofi flunks MS study, dealing another blow to Denali pact

Sanofi tore the RIPK1 inhibitor trial from its list of active studies after failing to meet its primary and secondary endpoints.
Nick Paul Taylor Oct 11, 2024 5:56am
positive negative up down good bad mixed

Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies

Sep 20, 2024 7:07am
plan B fail reroute road path trail miss

Sanofi's tolebrutinib fails 2 of 3 late-stage MS trials

Sep 2, 2024 1:00am
brain amyloid alzheimers strings detailed web complicated thought

Siemens Healthineers nets CE Mark for MS relapse risk blood test

Jun 17, 2024 11:30am
IPO initial public offering Wall Street

Contineum lowers expectations for $110M IPO

Apr 5, 2024 7:00am
Graphic image of the letters IPO in white in front of a yellow background

J&J-allied bio files IPO to take fight to BMS, Roche and more

Mar 18, 2024 7:15am